Page last updated: 2024-08-21

indazoles and Hematologic Neoplasms

indazoles has been researched along with Hematologic Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Davare, MA; Druker, BJ; Joshi, SK; Tognon, CE	1
Bisson, WH; Bottomly, D; Davare, MA; Druker, BJ; Huang, A; Joshi, SK; McWeeney, SK; Qian, K; Tognon, CE; Traer, E; Tyner, JW; Watanabe-Smith, K	1
Brega, N; Hinson, JM; Houk, BE; Jillela, A; Reddy, N; Voorhees, PM	1

Reviews

1 review(s) available for indazoles and Hematologic Neoplasms

Article	Year
Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia, 2019, Volume: 33, Issue:11 Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Indazoles; Mice; Oncogenes; Point Mutation; Prognosis; Pyrazoles; Pyrimidines; Receptor, trkA; Zebrafish	2019

Trials

1 trial(s) available for indazoles and Hematologic Neoplasms

Article	Year
Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; Glycine; Hematologic Neoplasms; HSP90 Heat-Shock Proteins; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult	2013

Article

Year

Phase I trial of the HSP90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies.

Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; Glycine; Hematologic Neoplasms; HSP90 Heat-Shock Proteins; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult

2013

Other Studies

1 other study(ies) available for indazoles and Hematologic Neoplasms

Article	Year
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. Blood, 2020, 06-11, Volume: 135, Issue:24 Topics: Animals; Base Sequence; Benzamides; Cell Line; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Indazoles; Lipid Metabolism; Membrane Glycoproteins; Mice; Mutant Proteins; Oncogenes; Point Mutation; Protein Kinase Inhibitors; Protein Multimerization; Receptor, trkB; Receptor, trkC; Recombinant Proteins; RNA, Small Interfering	2020

Article

Year

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.

Blood, 2020, 06-11, Volume: 135, Issue:24

Topics: Animals; Base Sequence; Benzamides; Cell Line; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Indazoles; Lipid Metabolism; Membrane Glycoproteins; Mice; Mutant Proteins; Oncogenes; Point Mutation; Protein Kinase Inhibitors; Protein Multimerization; Receptor, trkB; Receptor, trkC; Recombinant Proteins; RNA, Small Interfering

2020